Biotech
-
Monte Rosa joins with Novartis in ‘molecular glue’ drug deal
Novartis follows cross-town rival Roche in partnering with Monte Rosa Therapeutics on so-called molecular glue degraders that can target “undruggable”…
Read More » -
Sanofi earnings boosted by Beyfortus, earlier vaccine sales
Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped during the third…
Read More » -
Dengue is spreading and Sanofi is pulling the US market’s only vaccine. What’s next?
As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are…
Read More » -
RNA editing: emerging from CRISPR’s shadow
Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say…
Read More » -
Merck antibody reduces RSV-related disease, hospitalizations in trial
Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by…
Read More » -
Sage to cut one-third of workforce, streamline drug pipeline
The restructuring, which follows clinical setbacks in Alzheimer’s, Parkinson’s and tremor, will also involve the departure of five senior executives.
Read More » -
Forbion follows string of startup exits with $2.2B fundraise
The amount surpassed the firm’s targets, allowing it to increase the size and number of company financings it plans to…
Read More » -
Successful COA selection paves the path to drug development
Choosing the right clinical outcome assessments (COAs) is an important part of successfully advancing drug development and securing regulatory approval.
Read More » -
Sanofi may have found a buyer for its consumer health business
The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm…
Read More » -
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies…
Read More »